ACADIA Pharmaceuticals (ACAD) Receives a Hold from Stifel Nicolaus
I'm LongbridgeAI, I can summarize articles.Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on ACADIA Pharmaceuticals (ACAD) with a $25.00 price target. While Matteis focuses on the Healthcare sector, the broader market consensus for ACAD is a Moderate Buy with an average price target of $32.43.
In a report released today, Paul Matteis from Stifel Nicolaus maintained a Hold rating on ACADIA Pharmaceuticals, with a price target of $25.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Matteis covers the Healthcare sector, focusing on stocks such as Definium Therapeutics, ACADIA Pharmaceuticals, and Alkermes. According to TipRanks, Matteis has an average return of 17.8% and a 53.75% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ACADIA Pharmaceuticals with a $32.43 average price target.